Mrna

• Merck and Moderna announced Wednesday that a personalized mRNA-based cancer vaccine successfully extended the lifespan of melanoma patients in a large, late-stage trial. • The companies intend to present the trial data at an upcoming international medical meeting to begin discussions with regulators regarding official filing submissions for approval. • This development is significant as it demonstrates the potential of personalized mRNA technology to treat aggressive cancers more effectively than traditional methods.

• Researchers are developing next-generation mRNA vaccines designed to direct the human immune system to attack and disassemble tumors tailored to an individual's specific cancer. • While current breakthroughs are promising for melanoma—which sees roughly 112,000 new U.S. cases annually—clinical trials are expanding to target hard-to-treat cancers of the lungs, bladder, kidney, and pancreas. • This shift represents a potential new era of personalized medicine that could revolutionize oncology by moving beyond traditional treatments to targeted immunotherapy.

• Moderna and Merck announced that a personalized mRNA cancer vaccine successfully slowed the recurrence and spread of melanoma in a late-stage clinical trial. • The vaccine was administered in combination with Merck's immunotherapy drug, Keytruda, to enhance the body's immune response against the cancer. • This result is significant as it demonstrates the potential for mRNA technology to be adapted for oncology, moving beyond its success in COVID-19 vaccinations.

• Merck and Moderna announced that their personalized mRNA vaccine successfully met its goals in a late-stage trial by preventing skin cancer from returning in high-risk melanoma patients. • While the results have been met with enthusiasm from observers, the companies have not yet released the full data from the ongoing study. • This development marks a significant step in applying mRNA technology to oncology, following Moderna's recent FDA approval for an mRNA flu shot.

• The FDA has approved mFLUSIVA, a new mRNA-based flu vaccine designed to provide enhanced protection for older adults. • Clinical trials demonstrated the vaccine is highly effective in preventing serious illness for adults aged 50 to 64, with accelerated approval granted for those 65 and older. • This approval is significant as it introduces mRNA technology to flu prevention for aging populations ahead of the 2026–2027 flu season.

• The U.S. Food and Drug Administration (FDA) has officially approved a new mRNA-based vaccine designed to combat influenza. • Despite this milestone, experts caution that the approval does not necessarily signal a broad government embrace of mRNA technology for all vaccines. • This development is significant as it expands the application of mRNA platforms beyond COVID-19, potentially streamlining the response to seasonal flu mutations.

• The FDA has approved the first mRNA-based influenza vaccine, reversing a previous decision earlier this year to decline the application's review. • The approval covers adults aged 50 to 64, while those aged 65 and older have received accelerated approval. • This decision follows a large-scale clinical trial that yielded largely favorable results, despite an unusual initial rejection by the agency.

• The FDA has authorized Moderna’s mFlusiva, marking the first mRNA-based flu vaccine approved for use in older adults. • Separately, U.S. health officials are reviewing the nation's measles elimination status following 38 new outbreaks in 2026. • In a legal ruling, a judge designated Meta’s platforms as a "public nuisance," ordering the company to fund mental health remediation efforts.

• The FDA has approved the first-of-its-kind mRNA-based flu vaccine specifically for adults aged 50 and older. • This approval follows a severe 2024-25 flu season, which the CDC estimates resulted in approximately 45,000 deaths. • The shift to mRNA technology is significant as it offers the potential for more effective, rapidly adaptable vaccines compared to traditional methods.

• The FDA has approved mFlusiva, marking the first time an mRNA-based vaccine has been authorized for the prevention of influenza. • Unlike traditional flu vaccines, mRNA technology allows manufacturers to produce shots more rapidly, reducing the likelihood of a mismatch between the vaccine and circulating strains. • Medical experts, including Dr. Paul Pottinger of UW Medical Center, describe the approval as a significant advancement in public health.

• The FDA has approved Moderna's new mRNA-based flu vaccine, named mFlusiva, which is specifically intended for adults aged 50 and older. • This approval marks a shift toward using mRNA technology for seasonal influenza, moving away from traditional egg-based vaccine production methods. • The development is significant as it aims to provide more precise and potentially more effective protection against evolving flu strains.

• The FDA approved mFlusiva, the first mRNA-based flu vaccine developed by Moderna, on Wednesday. • The vaccine is approved for adults aged 50 to 65 and those 65 and older, with late-stage trials showing it is approximately 27% more effective than standard flu shots. • This approval is significant as it applies the same messenger RNA platform used in Pfizer and Moderna's COVID-19 vaccines to seasonal influenza.

• Health Canada has authorized Moderna to begin a clinical trial for an mRNA vaccine targeting the Bundibugyo strain of the Ebola virus. • The trial aims to combat a significant and ongoing outbreak of the virus currently surging throughout the Democratic Republic of the Congo. • This authorization is critical as it leverages mRNA technology to provide a rapid response to a deadly pathogen in a region facing a public health crisis.

• Moderna has launched a first-in-human Phase 1 clinical trial (NCT07737717) for mRNA-1469, an investigational vaccine targeting the Bundibugyo ebolavirus (BDBV). • The study is being conducted across three sites in Canada and aims to enroll approximately 80 healthy adult participants to evaluate safety, tolerability, and immunogenicity. • This development is critical because while vaccines exist for Zaire ebolavirus, there are currently no approved vaccines to protect against BDBV, which has caused outbreaks in the Democratic Republic of the Congo.

• The U.S. FDA has approved Moderna's first mRNA-based influenza vaccine specifically for adults aged 50 and older. • This decision follows a reversal of a previous refusal and leverages mRNA technology that was rapidly accelerated and proven safe during the COVID-19 pandemic. • The approval is significant as it expands the use of mRNA technology to combat seasonal diseases, while Health Canada is currently considering its own approval of the shot.

• Health officials have approved mFLUSIVA, the first mRNA-based flu vaccine developed by Moderna, which is expected to be available by the next flu season. • Clinical data indicates the shot may be 27% more effective than traditional vaccines, though side effects like fatigue and headaches occurred in up to two-thirds of patients. • The rollout follows a severe winter flu season characterized by a virulent strain that led to record-high case numbers across multiple US states.

• Health Canada has approved a Phase I clinical trial for Moderna’s mRNA vaccine candidate targeting the Bundibugyo virus, a species of Ebola. • Canada becomes the second nation to authorize this trial, following a similar approval in the United Kingdom. • The move comes after the World Health Organization declared the current outbreak a public health emergency of international concern on May 17.

• The FDA has approved the first mRNA-based flu vaccine, developed by Moderna, specifically for adults aged 50 and older. • Former FDA vaccine regulator Jesse Goodman noted the shot's documented superiority in effectiveness over standard doses for the 50-64 age group, particularly those with underlying health conditions. • The new vaccine serves as a potent alternative for seniors 65 and over and will be covered by Medicare, according to KFF health policy expert Jennifer Kates.

• The FDA has approved Moderna's mFLUSIVA, the first seasonal influenza vaccine utilizing mRNA technology to receive official authorization. • The vaccine is specifically approved for use in adults aged 50 and older, marking a significant milestone for the drugmaker's mRNA platform. • This approval is critical as it demonstrates the potential for mRNA technology to address broader public health challenges beyond COVID-19.

• The FDA has approved mFlusiva, the first mRNA-based influenza vaccine developed by Moderna, specifically targeting adults aged 50 and older. • The regulatory strategy includes full approval for adults aged 50 to 64 and accelerated approval for those 65 and older, pending a postmarketing study using a high-dose comparator. • This approval follows a unanimous recommendation from the FDA’s Vaccines and Related Biological Products Advisory Committee in June 2026.

The mFlusiva vaccine for older people is first made with mRNA platform key to ending coronavirus pandemicThe Food and Drug Administration has approved a new kind of flu vaccine for older people, the first made with the same mRNA technology that was key to ending the Covid-19 pandemic, Moderna, the manufacturer, said.The shot, named mFlusiva, is intended for adults aged 50 or older. Other brands of flu shots already have begun arriving in pharmacies ahead of fall vaccination season, and Moderna said late on Wednesday that it expected some of its new version to be available soon at select retailers. Continue reading...

• The FDA has approved Moderna’s mFlusiva, marking the first time a licensed influenza vaccine has been developed using messenger RNA (mRNA) technology. • This approval represents a significant milestone for mRNA, a platform that gained global prominence during the COVID-19 pandemic but has faced scrutiny from vaccine skeptics. • The shift to mRNA for flu shots is critical because the technology allows for faster production and potentially better matching to evolving seasonal virus strains.

• A comprehensive review published in The Lancet reaffirms that approved mRNA vaccines are safe and highly effective across diverse populations, including children and immunocompromised patients. • Led by researchers from the University of British Columbia and Imperial College London, the study analyzed data from billions of doses, combining clinical trials with real-world surveillance. • The findings confirm that these vaccines significantly reduce documented SARS-CoV-2 infections, hospitalizations, and mortality within 14 to 42 days post-vaccination.

• A new review published in The Lancet on Tuesday confirms that mRNA vaccines from Pfizer-BioNTech and Moderna are safe and effective. • Led by Manish Sadarangani of B.C. Children's Hospital, researchers analyzed laboratory data, clinical trials, and real-world surveillance from January 2020 through December 2025. • The findings are significant because they validate the scientific and public health impact of mRNA technology during the pandemic.

Moderna seeks FDA approval of its new shot, mFlusvia, as option for 50 and olderUS health advisers are debating a new kind of flu vaccine Thursday, the first made with the same mRNA technology that was key to ending the Covid-19 pandemic.Moderna is seeking Food and Drug Administration (FDA) approval of its new shot , dubbed mFlusiva, as an option for people 50 and older. The FDA advisory committee meeting is a step toward a final decision ahead of the winter flu season. Continue reading...

• An mRNA vaccine demonstrated potential in a trial with 16 pancreatic cancer patients, reducing recurrence risk post-surgery according to Nature journal. • Eight patients responded positively, stimulating long-term immune responses as noted by Forbes. • Pancreatic cancer has a 12% five-year survival rate; this could transform outcomes for the 66,000 annual US cases if scaled.

• The FDA granted approval on April 7, 2026, to Moderna's mRESVIA vaccine, an mRNA-based shot targeting respiratory syncytial virus (RSV) for adults aged 60 and older. • Clinical trials showed 83.7% efficacy against RSV lower respiratory tract disease in the first season, with data from over 37,000 participants across 22 countries including US sites. • This marks the second mRNA RSV vaccine approved after GSK's Arexvy, aiming to reduce 140,000-160,000 annual US hospitalizations among seniors; CDC review expected soon.